Maryland State Retirement & Pension System Has $705,000 Stock Holdings in TG Therapeutics, Inc. $TGTX

Maryland State Retirement & Pension System decreased its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 51.1% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 19,506 shares of the biopharmaceutical company’s stock after selling 20,347 shares during the period. Maryland State Retirement & Pension System’s holdings in TG Therapeutics were worth $705,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of TGTX. Royal Bank of Canada lifted its position in TG Therapeutics by 16.4% during the first quarter. Royal Bank of Canada now owns 75,692 shares of the biopharmaceutical company’s stock worth $2,985,000 after acquiring an additional 10,660 shares during the last quarter. NewEdge Advisors LLC lifted its holdings in TG Therapeutics by 9.6% during the 1st quarter. NewEdge Advisors LLC now owns 7,593 shares of the biopharmaceutical company’s stock worth $299,000 after purchasing an additional 665 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in TG Therapeutics by 21.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company’s stock valued at $75,683,000 after purchasing an additional 345,059 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in TG Therapeutics by 5.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 287,059 shares of the biopharmaceutical company’s stock valued at $11,319,000 after buying an additional 14,689 shares in the last quarter. Finally, State of Alaska Department of Revenue increased its position in TG Therapeutics by 9.2% during the 2nd quarter. State of Alaska Department of Revenue now owns 80,783 shares of the biopharmaceutical company’s stock worth $2,906,000 after buying an additional 6,827 shares during the period. 58.58% of the stock is owned by institutional investors.

TG Therapeutics Stock Performance

Shares of TG Therapeutics stock opened at $31.57 on Thursday. The company has a 50 day moving average of $30.78 and a 200-day moving average of $32.38. TG Therapeutics, Inc. has a 1-year low of $25.28 and a 1-year high of $46.48. The company has a current ratio of 3.82, a quick ratio of 2.89 and a debt-to-equity ratio of 0.40. The company has a market cap of $5.01 billion, a PE ratio of 11.36 and a beta of 1.86.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $2.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $2.19. TG Therapeutics had a net margin of 84.13% and a return on equity of 133.24%. The business had revenue of $161.71 million for the quarter, compared to analysts’ expectations of $152.12 million. During the same period last year, the firm posted $0.02 earnings per share. The firm’s quarterly revenue was up 92.7% compared to the same quarter last year. As a group, equities research analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. The Goldman Sachs Group boosted their target price on shares of TG Therapeutics from $37.00 to $39.00 and gave the company a “neutral” rating in a research report on Thursday, January 15th. JPMorgan Chase & Co. increased their target price on shares of TG Therapeutics from $46.00 to $49.00 and gave the stock an “overweight” rating in a research report on Monday, November 3rd. B. Riley upgraded shares of TG Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 4th. Weiss Ratings reiterated a “hold (c+)” rating on shares of TG Therapeutics in a research note on Monday, December 29th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of TG Therapeutics in a research note on Wednesday, January 14th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, TG Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $50.75.

Insider Activity

In other news, Director Yann Echelard sold 5,000 shares of the business’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $32.57, for a total transaction of $162,850.00. Following the completion of the transaction, the director owned 223,816 shares of the company’s stock, valued at approximately $7,289,687.12. The trade was a 2.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 10.64% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.